UK company secures prestigious Queen's Award for export of recombinant human albumin for manufacture of safer medicines
Delta Biotechnology has been recognised with a Queen's Award for Enterprise, the most prestigious award of its kind available to companies in the UK.
Delta employs approximately 100 people in Nottingham, UK, and claims to have spearheaded the development of the growing biotechnology industry in the East Midlands.
"This award recognises the substantial contribution Delta has made to the local economy and the awareness of UK biotechnology capabilities across the globe," commented Werner Merkle, CEO.
He adds: "The achievement of this award is a resounding endorsement of the sustained effort and dedication of the Delta employees over the years".
The number of companies using and evaluating Delta's products and technologies world-wide continues to grow, it says, and reflects the top tier organisations in the pharmaceutical and biotechnology sectors.
The company says it is a world leader in the development and manufacture of recombinant proteins from baker's yeast, Saccharomyces cerevisiae.
"Our business model is based on the licensing of our high-yielding protein expression technology, our albumin fusion platform, Albufuse, and the commercialisation of products based on these technologies.
"We have also developed the world's first recombinant protein drug excipient, Recombumin, a recombinant human albumin which we manufacture at our FDA-inspected facility," added Merkle.
"All our business platforms use the animal-free benefit provided by working with yeast.
"We have licensed our technologies to a number of global pharmaceutical and US biotech concerns".
The awards are made each year by Queen Elizabeth II, on the advice of the prime minister, who is assisted by an advisory committee that includes representatives of government, industry and commerce, and trade unions.
